muramylnac-ala-isogln-lys-tripeptide has been researched along with Melanoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mutsuura, S; Ogawara, M; Sone, S; Tsubura, E | 1 |
| Erickson, KL; Fidler, IJ; Fogler, WE; Kleinerman, ES; Schroit, AJ | 1 |
| Favaro, D; Freschi, A; Galligioni, E; Quaia, M; Santarosa, M; Spada, A; Talmini, R | 1 |
| Dubielzig, RR; Everlith, K; Fidel, J; Fox, LE; Henry, C; Kurzman, ID; MacEwen, EG; Madewell, BR; Obradovich, J; Phillips, B; Rodriguez, CO; Rosenberg, M; Rosenthal, RC; Vail, DM; Zwahlen, CH | 1 |
| Nii, A; Ogawara, M; Ogura, T; Shimizu, E; Sone, S; Tandon, P; Utsugi, T | 1 |
1 trial(s) available for muramylnac-ala-isogln-lys-tripeptide and Melanoma
| Article | Year |
|---|---|
Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Combined Modality Therapy; Cytotoxicity Tests, Immunologic; Dog Diseases; Dogs; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Liposomes; Male; Melanoma; Mouth Neoplasms; Survival Analysis | 1999 |
4 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and Melanoma
| Article | Year |
|---|---|
Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adult; Cytotoxicity, Immunologic; Dose-Response Relationship, Immunologic; Humans; Immunity, Cellular; Liposomes; Macrophage Activation; Melanoma; Monocytes; Time Factors | 1984 |
Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Carcinoma; Cells, Cultured; Cytotoxicity, Immunologic; Humans; Kidney; Liposomes; Lung; Macrophage Activation; Melanoma; Monocytes; Phagocytosis | 1983 |
Soluble intercellular adhesion molecule-1 in melanoma patients treated with liposomes containing muramyl tripeptide.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Cytokines; Humans; Intercellular Adhesion Molecule-1; Liposomes; Melanoma; Skin Neoplasms | 1995 |
Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Cell Line; Drug Synergism; Humans; Interferon-gamma; Liposomes; Lymphocyte Activation; Melanoma; Monocytes; Phagocytosis; Recombinant Proteins | 1986 |